Clinical Trial Update: Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19 [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for TriCAR-T_CD19 in refractory/relapsed non-Hodgkin lymphoma (Phase 1/Phase 2) with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• TriCAR-T_CD19 (TriCAR-T_CD19)

Snippet

Sponsor: Timmune Biotech Inc. | Conditions: Non-hodgkin Lymphoma,B Cell | Phase 1, Phase 2 | Status: UNKNOWN